Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
Rusthoven, J., Eisenhauer, E., Butts, C., Gregg, R., Dancey, J., Fisher, B., Iglesias, J.Volume:
33
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(97)85830-3
Date:
September, 1997
File:
PDF, 261 KB
english, 1997